Friday 6 November 2026
Export TRLV’s income statement to Excel — free account
Trulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
11.42
0.52
+4.77%
Follow TRLV
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 5 | 5 | 4 |
| (9.73%) | (6.85%) | (47.92%) | (45.52%) | ||
| (4.18%) | (2.86%) | (18.93%) | (17.61%) | ||
ROIC |
7.61% | 7.77% | (21.87%) | 0.00% | |
Return on Tangible Assets |
(10.52%) | (6.73%) | (44.92%) | (42.29%) | |
Average Days of Receivables |
5.86 | 6.49 | 8.66 | 0.00 | |
Free Cash Flow per Share |
1.11 | 1.16 | 0.97 | 1.26 | |
Free Cash Flow |
212.31 | 224.20 | 186.25 | 242.48 | |
Capital Expenditures |
(60.51) | (53.20) | (58.20) | — | |
| Other line items | |||||
Cash ROIC |
12.56% | 12.04% | 12.97% | 31.43% | |
Accounts Receivable Turnover |
63.42 | 58.96 | 50.51 | 0.00 | |
Accounts Payable Turnover |
5.32 | 5.55 | 6.57 | 5.69 | |
Inventory Turnover |
1.98 | 1.96 | 2.16 | 1.96 | |
Average Days of Payables |
64.19 | 61.02 | 48.62 | 58.49 | |
Days of Inventory on Hand |
188.16 | 187.33 | 147.75 | 163.69 | |
Tax Rate |
(2.28) | (1.84) | 0.44 | 0.36 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
37.69% | 36.86% | 37.93% | 38.93% | |
Share Based Compensation of Revenue |
1.73% | 1.77% | 1.83% | 1.94% | |
Interest Coverage |
2.26 | 2.38 | (4.84) | 0.00 | |
Operating CF/Net income |
(2.34) | (3.42) | (0.52) | (0.54) | |
Depreciation/Fixed assets |
0.26 | 0.26 | 0.29 | 0.00 | |
Capex/Depreciation |
(0.35) | (0.31) | (0.34) | — | |
Revenue per Share |
6.17 | 6.08 | 5.91 | 5.60 | |
Operating CF per Share |
1.43 | 1.44 | 1.27 | 1.26 | |
Capex per Share |
(0.32) | (0.28) | (0.30) | 0.00 | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026